ANDOVER, Mass. and LONDON, Sept. 4, 2016 /PRNewswire/ -- ndd Medical Technologies, Inc. is holding a practical workshop on performing multi-breath nitrogen washout (MLB) testing to facilitate diagnosis of small airways diseases, this afternoon at the ERS International Congress 2016 in London, England. The workshop, on the utility of the Lung Clearance Index (LCI) in a standard clinical environment, will be led by Prof. Dr. Monika Gappa, Chief of Pediatrics at the Marien-Hospital in Wesel and twice voted among Germany's top doctors.
LCI is already used worldwide to monitor patients with cystic fibrosis (CF). The workshop aims to help physicians interested in introducing LCI to their practice.
Studies have found the LCI to be as good as high-resolution computed tomography (CT) and more sensitive than FEV1 in measuring changes in lung function. There can be significant changes in LCI without notable changes in FEV1, alerting physicians to the need for earlier intervention.
Research also shows that the LCI, derived from multiple-breath nitrogen washout tests, is useful with other respiratory diseases, including non-CF bronchiectasis. The test is easier to perform in children than conventional lung function testing.
ndd Medical's mobile EasyOne Pro LAB performs MBW, LCI testing anywhere
Multi-breath nitrogen washout testing is simplified with the mobile, ultrasound-based EasyOne Pro LAB, which in addition performs the full range of pulmonary function tests including DLCO and FEV1. The single breath diffusing capacity of the lungs (DLCO), measuring the ability of the lungs to transfer oxygen from inhaled air to the red blood cells in pulmonary capillaries, is considered to be one of the most clinically valuable tests of lung function.
Known for its accurate, reproducible results and ease of use, ndd Medical's point-of-service ultrasound technology—requiring no calibration, no altitude adjustment, no maintenance and no disposables other than spirettes® and bariettes™--makes the EasyOne line of PFT devices ideal for researchers and clinicians.
"Our EasyOne Plus has achieved 40 percent market-leading share in spirometry for these reasons, and our EasyOne Pro and EasyOne Pro LAB make full PFT testing available wherever the patient is—in the office, clinic, lab, hospital or at a mobile screening event," said Georg Harnoncourt, CEO of ndd Medical Technologies.
ndd Medical sponsors Leonard Nimoy (a.k.a. Mr. Spock) COPD documentary
The soon-to-be released documentary COPD: Highly Illogical about Leonard Nimoy's struggle with COPD and the benefits of early diagnosis is sponsored in part by ndd Medical. For more information about the film, and the latest in COPD detection technology, please visit ndd Medical's booth E.08 at ERS.
Best respiratory physiology abstract winner announced
The winner of the ERS Grant for Best Abstract in Paediatric Respiratory Physiology, sponsored by ndd Medical Technologies,is Andrea Crespo Sedano for her research on diagnosing of paediatric sleep apnea.
About ndd Medical Technologies, Inc.
With 40 percent of the U.S. spirometry market share, ndd Medical Technologies offers innovative, easy-to-use pulmonary function testing instruments that help clinicians diagnose lung disease with greater precision for optimal treatment. Its EasyOne® and EasyOne Pro portable instruments take up just 12 inches of space to take lung function testing wherever it is needed, measuring DLCO, FRC, LCI and FVC. Ndd's patented Ultrasonic TrueFlow™ technology, which requires no calibration, eliminates problems associated with traditional methods of flow measurement, making testing fast, reliable and error free. To learn more, visit www.nddmed.com.
Please visit us at ERS Booth E.08
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ndd-medicals-easyone-pro-lab-point-of-service-pft-devices-facilitate-diagnosis-of-small-airways-diseases-300321562.html
SOURCE ndd Medical Technologies, Inc.